MFAP2

Summary

MFAP2 (microfibril associated protein 2, HGNC:7033) is a protein-coding gene on chromosome 1p36.13, encoding Microfibrillar-associated protein 2 (P55001). Component of the elastin-associated microfibrils.

Microfibrillar-associated protein 2 is a major antigen of elastin-associated microfibrils and a candidate for involvement in the etiology of inherited connective tissue diseases. Four transcript variants encoding two different isoforms have been found for this gene.

Source: NCBI Gene 4237 — RefSeq curated summary.

At a glance

• GWAS associations: 65
• Clinical variants (ClinVar): 40 total
• MANE Select transcript: NM_002403

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:7033
Approved symbol	MFAP2
Name	microfibril associated protein 2
Location	1p36.13
Locus type	gene with protein product
Status	Approved
Aliases	MAGP, MAGP-1
Ensembl gene	ENSG00000117122
Ensembl biotype	protein_coding
OMIM	156790
Entrez	4237

Gene structure

Transcript identifiers

Ensembl transcripts: 26 — 22 protein_coding, 4 protein_coding_CDS_not_defined

ENST00000375534, ENST00000375535, ENST00000476788, ENST00000478684, ENST00000490075, ENST00000492598, ENST00000884385, ENST00000884386, ENST00000884387, ENST00000884388, ENST00000884389, ENST00000930328, ENST00000930329, ENST00000930330, ENST00000930331, ENST00000930332, ENST00000930333, ENST00000930334, ENST00000930335, ENST00000930336, ENST00000930337, ENST00000930338, ENST00000930339, ENST00000930340, ENST00000930341, ENST00000954861

RefSeq mRNA: 4 — MANE Select: NM_002403 NM_001135247, NM_001135248, NM_002403, NM_017459

CCDS: CCDS174, CCDS44071

Canonical transcript exons

ENST00000375535 — 9 exons

Exon	Start	End
ENSE00001925438	16980587	16980620
ENSE00003480746	16976897	16976923
ENSE00003487163	16975269	16975342
ENSE00003540338	16975643	16975730
ENSE00003545261	16977109	16977198
ENSE00003625320	16976501	16976545
ENSE00003644006	16978237	16978314
ENSE00003664286	16976708	16976794
ENSE00003689974	16974502	16975023

Expression profiles

Bgee: expression breadth ubiquitous, 132 present calls, max score 98.65.

FANTOM5 (CAGE): breadth ubiquitous, TPM avg 57.8569 / max 585.1303, expressed in 1276 samples.

FANTOM5 promoters (6 alternative TSS)

Promoter ID	TPM avg	Samples expressed
10558	47.6157	1235
10562	6.2216	662
10559	2.1679	876
10557	0.7320	436
10560	0.7288	287
10561	0.3909	217

Top tissues by expression

134 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
stromal cell of endometrium	CL:0002255	98.65	gold quality
ventricular zone	UBERON:0003053	97.79	gold quality
gall bladder	UBERON:0002110	97.38	gold quality
endocervix	UBERON:0000458	96.96	gold quality
right coronary artery	UBERON:0001625	96.37	gold quality
ganglionic eminence	UBERON:0004023	96.34	gold quality
placenta	UBERON:0001987	95.72	gold quality
descending thoracic aorta	UBERON:0002345	95.67	gold quality
thoracic aorta	UBERON:0001515	95.30	gold quality
ascending aorta	UBERON:0001496	95.28	gold quality
body of uterus	UBERON:0009853	95.05	gold quality
ectocervix	UBERON:0012249	94.54	gold quality
mucosa of stomach	UBERON:0001199	94.49	gold quality
left coronary artery	UBERON:0001626	94.29	gold quality
uterine cervix	UBERON:0000002	93.85	gold quality
myometrium	UBERON:0001296	92.79	gold quality
smooth muscle tissue	UBERON:0001135	92.46	gold quality
right ovary	UBERON:0002118	92.28	gold quality
vagina	UBERON:0000996	92.14	gold quality
ovary	UBERON:0000992	92.08	gold quality
left ovary	UBERON:0002119	92.00	gold quality
left uterine tube	UBERON:0001303	91.79	gold quality
popliteal artery	UBERON:0002250	91.25	gold quality
tibial artery	UBERON:0007610	91.24	gold quality
subcutaneous adipose tissue	UBERON:0002190	91.12	gold quality
primordial germ cell in gonad	CL:0000670 ∩ UBERON:0000991	90.87	gold quality
adipose tissue	UBERON:0001013	89.82	gold quality
skin of leg	UBERON:0001511	89.54	gold quality
fallopian tube	UBERON:0003889	88.74	gold quality
zone of skin	UBERON:0000014	88.60	gold quality

Single-cell (SCXA)

Detected in 8 experiment(s), a significant marker in 7.

Experiment	Marker?	Max mean expression
E-MTAB-9154	yes	417.10
E-MTAB-6701	yes	57.76
E-HCAD-10	yes	46.34
E-MTAB-8410	yes	38.43
E-MTAB-6678	yes	17.62
E-ANND-3	yes	15.68
E-MTAB-10042	yes	8.03
E-CURD-95	no	59.39

Regulation

Is transcription factor: no

miRNA regulators (miRDB)

19 targeting MFAP2, top 30 by miRDB confidence (max_score; target_count = how many genes the miRNA targets in total — lower means more specific):

miRNA	Max score	Avg score	miRNA target_count
HSA-MIR-3163	100.00	77.23	8605
HSA-MIR-4692	100.00	67.32	2066
HSA-MIR-568	99.98	69.86	2084
HSA-MIR-4775	99.98	75.00	6394
HSA-MIR-548AJ-3P	99.96	73.38	5345
HSA-MIR-548X-3P	99.96	73.38	5345
HSA-MIR-548J-3P	99.94	72.61	4881
HSA-MIR-548AE-3P	99.93	72.66	4867
HSA-MIR-548AH-3P	99.93	72.54	4872
HSA-MIR-548AM-3P	99.93	72.54	4872
HSA-MIR-548AQ-3P	99.93	72.66	4867
HSA-MIR-6835-3P	99.93	70.49	2904
HSA-MIR-498-3P	99.91	71.27	1114
HSA-MIR-8065	99.19	70.38	1289
HSA-MIR-6770-5P	98.97	66.76	1853
HSA-MIR-3149	98.77	67.13	1639
HSA-MIR-12120	98.05	68.44	1768
HSA-MIR-6872-3P	97.08	66.99	750
HSA-MIR-3943	95.87	64.57	523

Literature-anchored findings (GeneRIF, showing 14)

• These results demonstrate that microfibril-associated glycoprotein-1 is capable of cumulative binding to distinct regions on tropoelastin, with different apparent dissociation constants and different amounts of bound protein. (PMID:15233806)
• microfibrillar proteins MAGP-1 and MAGP-2 can function outside of their role in elastic fibers to activate a cellular signaling pathway (PMID:16492672)
• Study suggests a dual role for MAGP1, with extracellular MAGP1A involved in ECM function, and intracellular MAGP1B modulating the expression of genes that function in cell adhesion, migration and control of ECM deposition. (PMID:17692555)
• Demonstrate specific immunolocalization of fibrillin-1, MAGP-1, and LTBP-1 with elastin in the outer annulus fibrosus of the fetal human intravertebral disc. (PMID:21540769)
• Decreased MFAP2 gene expression in the endometrium of patients with implantation failure after in vitro ertilization treatment. (PMID:22885067)
• Our characterization of alternative forms of MAGP2 present in the extracellular space not only enhances diversity of this ECM protein but also provides a previously unrecognized molecular mechanism for regulation of MAGP2 biological activity. (PMID:23201136)
• Data show that MAGP-1, component of the extracellular matrix interact with fibrillin and impart unique biological properties that influence microfibril function. Mutations in MAGP-1 have been linked to thoracic aneurysms and metabolic diseases and mice lacking either one have defects in multiple organ systems, reflecting the widespread distribution of microfibrils in vertebrate tissues. [review] (PMID:29524629)
• Integrated profiling identifies SLC5A6 and MFAP2 as novel diagnostic and prognostic biomarkers in gastric cancer patients. (PMID:31894266)
• MFAP2 Promotes the Proliferation of Cancer Cells and Is Associated With a Poor Prognosis in Hepatocellular Carcinoma. (PMID:33280519)
• Genome-Scale Analysis Identified NID2, SPARC, and MFAP2 as Prognosis Markers of Overall Survival in Gastric Cancer. (PMID:33758160)
• Decreased Levels of Microfibril-Associated Glycoprotein (MAGP)-1 in Patients with Colon Cancer and Obesity Are Associated with Changes in Extracellular Matrix Remodelling. (PMID:34445187)
• MFAP2 aggravates tumor progression through activating FOXM1/beta-catenin-mediated glycolysis in ovarian cancer. (PMID:35546486)
• MAGP1 maintains tumorigenicity and angiogenesis of laryngeal cancer by activating Wnt/beta-catenin/MMP7 pathway. (PMID:36645203)
• MFAP2 promotes the progression of oral squamous cell carcinoma by activating the Wnt/beta-catenin signaling pathway through autophagy. (PMID:37592847)

Cross-species orthologs

2 orthologs

Organism	Symbol	Gene ID
mus_musculus	Mfap2	ENSMUSG00000060572
rattus_norvegicus	Mfap2	ENSRNOG00000008257

Paralogs (1): MFAP5 (ENSG00000197614)

Protein

Protein identifiers

Microfibrillar-associated protein 2 — P55001 (reviewed: P55001)

Alternative names: Microfibril-associated glycoprotein 1

All UniProt accessions (1): P55001

UniProt curated annotations — full annotation on UniProt →

Function. Component of the elastin-associated microfibrils.

Subunit / interactions. Forms a ternary complex with BGN and ELN. Interacts with FBN1 (via N-terminal domain) and FBN2.

Subcellular location. Secreted. Extracellular space. Extracellular matrix.

Post-translational modifications. Forms intermolecular disulfide bonds either with other MAGP-1 molecules or with other components of the microfibrils. May form transglutaminase cross-links. O-glycosylated.

Similarity. Belongs to the MFAP family.

Isoforms (3)

UniProt ID	Names	Canonical?
P55001-1	A	yes
P55001-2	A'
P55001-3	B

RefSeq proteins (4): NP_001128719, NP_001128720, NP_002394, NP_059453 (=MANE)

Domains & families (InterPro)

ID	Name	Type
IPR003582	ShKT_dom	Domain
IPR008673	MAGP	Family

Pfam: PF05507

UniProt features (14 total): modified residue 4, disulfide bond 3, splice variant 2, signal peptide 1, chain 1, domain 1, region of interest 1, compositionally biased region 1

Structure

Experimental structures (PDB)

0 structures.

Predicted structure (AlphaFold)

Model	pLDDT	Fraction very-high
AF-P55001-F1	69.04	0.38

Functional residue map

Curated UniProt residues grouped by drug-discovery relevance — catalytic, ligand-binding, modification, and mutation-validated positions. Source: UniProtKB sequence features.

Post-translational modifications (4): 18, 47, 48, 50

Disulfide bonds (3): 160–176, 169–180, 153–183

Function

Pathways and Gene Ontology

Reactome pathways

3 pathways

ID	Pathway
R-HSA-1566948	Elastic fibre formation
R-HSA-2129379	Molecules associated with elastic fibres
R-HSA-1474244	Extracellular matrix organization

MSigDB gene sets: 177 (showing top): GOBP_MYELOID_CELL_DIFFERENTIATION, GSE18804_SPLEEN_MACROPHAGE_VS_COLON_TUMORAL_MACROPHAGE_UP, TGGTGCT_MIR29A_MIR29B_MIR29C, MODULE_52, DORN_ADENOVIRUS_INFECTION_12HR_UP, ZHAN_MULTIPLE_MYELOMA_MF_UP, MODULE_45, BILD_HRAS_ONCOGENIC_SIGNATURE, MODULE_118, GOBP_ANIMAL_ORGAN_MORPHOGENESIS, MYOD_01, GOBP_EMBRYONIC_ORGAN_MORPHOGENESIS, GOMF_EXTRACELLULAR_MATRIX_STRUCTURAL_CONSTITUENT, YANG_BREAST_CANCER_ESR1_DN, GOBP_PLATELET_MORPHOGENESIS

GO Biological Process (4): platelet formation (GO:0030220), embryonic eye morphogenesis (GO:0048048), post-embryonic eye morphogenesis (GO:0048050), positive regulation of cold-induced thermogenesis (GO:0120162)

GO Molecular Function (4): fibronectin binding (GO:0001968), fibrinogen binding (GO:0070051), extracellular matrix structural constituent (GO:0005201), protein binding (GO:0005515)

GO Cellular Component (3): microfibril (GO:0001527), extracellular region (GO:0005576), extracellular matrix (GO:0031012)

Reactome top-level categories

Rollup of top-2 pathways:

Category	Pathways
Extracellular matrix organization	1
Elastic fibre formation	1

GO top-level categories

Rollup of top GO terms by namespace:

Category	Terms
eye morphogenesis	2
myeloid cell differentiation	1
platelet morphogenesis	1
anatomical structure formation involved in morphogenesis	1
embryonic organ morphogenesis	1
positive regulation of multicellular organismal process	1
cold-induced thermogenesis	1
regulation of cold-induced thermogenesis	1
protein binding	1
protein-containing complex binding	1
structural molecule activity	1
extracellular matrix	1
binding	1
elastic fiber	1
supramolecular fiber	1
cellular anatomical structure	1
external encapsulating structure	1

Protein interactions and networks

STRING

804 interactions, top by confidence (×1000):

Protein A	Protein B	Partner UniProt	Score
MFAP2	FBN1	P35555	993
MFAP2	ELN	P15502	991
MFAP2	DCN	P07585	953
MFAP2	FBN2	P35556	948
MFAP2	MFAP1	P55081	912
MFAP2	MFAP3	P55082	889
MFAP2	BGN	P13247	794
MFAP2	LOX	P28300	769
MFAP2	FBLN5	Q9UBX5	723
MFAP2	MFAP5	Q13361	703
MFAP2	LOXL1	Q08397	664
MFAP2	LTBP2	Q14767	643
MFAP2	FBLN1	P23142	634
MFAP2	FBLN2	P98095	616
MFAP2	FN1	P02751	611

IntAct

5 interactions, top by confidence:

A	B	Type	Score
HOXA1	MFAP2	psi-mi:“MI:0915”(physical association)	0.560
	DDX3Y	psi-mi:“MI:0914”(association)	0.350
HOXA1	MFAP2	psi-mi:“MI:0915”(physical association)	0.000

BioGRID (8): MFAP2 (Affinity Capture-MS), MFAP2 (Two-hybrid), BGN (Reconstituted Complex), MFAP2 (Reconstituted Complex), COL4A3 (Reconstituted Complex), MFAP2 (Affinity Capture-MS), MFAP2 (Proximity Label-MS), MFAP2 (Proximity Label-MS)

ESM2 similar proteins: A0A088MLT8, A0JPH4, A2A8U2, A2ATD1, A6QLD2, B1AKI9, B1AL88, B3KU38, O14525, O35757, O75129, P0DPB3, P0DPB4, P12755, P17863, P27424, P49140, P55001, P55002, P85299, P97953, Q3V1G4, Q58CS8, Q5EGE1, Q5QQ56, Q5QQ57, Q60698, Q61137, Q68BL8, Q6DVA0, Q6L8S8, Q6L9W6, Q6S5C2, Q6ZWB6, Q80U62, Q80Z10, Q812A5, Q86Y38, Q8CCS2, Q8JG33

Diamond homologs: P27424, P55001, P55002, Q13361, Q28022, Q9QZJ6

SIGNOR signaling

0 interactions.

Disease & clinical

Clinical variants and AI predictions

ClinVar

40 variants total. Per-class counts are floors (≥ shown; pagination cap):

Classification	Count (floor)
Pathogenic	0
Likely pathogenic	0
Uncertain significance	23
Likely benign	1
Benign	0

Top pathogenic / likely-pathogenic (0)

SpliceAI

881 predictions. Top by Δscore:

Variant	Effect	Δscore
1:16975343:C:CC	acceptor_gain	1.0000
1:16975731:C:CC	acceptor_gain	1.0000
1:16976549:G:GC	acceptor_gain	1.0000
1:16976790:CACCT:C	acceptor_gain	1.0000
1:16976795:C:CC	acceptor_gain	1.0000
1:16976802:C:CT	acceptor_gain	1.0000
1:16976802:C:T	acceptor_gain	1.0000
1:16976803:A:T	acceptor_gain	1.0000
1:16977108:CCGAT:C	donor_gain	1.0000
1:16978232:CTTA:C	donor_loss	1.0000
1:16978233:TTA:T	donor_loss	1.0000
1:16978234:TA:T	donor_loss	1.0000
1:16978235:A:AC	donor_gain	1.0000
1:16978236:C:CC	donor_gain	1.0000
1:16978236:CCAGG:C	donor_gain	1.0000
1:16975263:TCCTA:T	donor_loss	0.9900
1:16975264:CCTAC:C	donor_loss	0.9900
1:16975265:CTACC:C	donor_loss	0.9900
1:16975266:TACC:T	donor_loss	0.9900
1:16975267:A:T	donor_loss	0.9900
1:16975268:C:CA	donor_loss	0.9900
1:16975341:GG:G	acceptor_gain	0.9900
1:16975344:T:C	acceptor_loss	0.9900
1:16975637:GCTCA:G	donor_loss	0.9900
1:16975639:TCACC:T	donor_loss	0.9900
1:16975641:A:T	donor_loss	0.9900
1:16975727:CAGT:C	acceptor_gain	0.9900
1:16975729:GT:G	acceptor_gain	0.9900
1:16975732:T:G	acceptor_loss	0.9900
1:16976545:TC:T	acceptor_loss	0.9900

AlphaMissense

1198 scored. Top likely-pathogenic:

Variant	Protein change	am_pathogenicity
1:16975307:C:G	C137S	0.999
1:16975307:C:T	C137Y	0.999
1:16975308:A:T	C137S	0.999
1:16975014:C:G	C153S	0.998
1:16975015:A:G	C153R	0.998
1:16975015:A:T	C153S	0.998
1:16975292:C:G	C142S	0.998
1:16975293:A:T	C142S	0.998
1:16975306:A:C	C137W	0.998
1:16975308:A:G	C137R	0.998
1:16975705:G:C	C104W	0.998
1:16975706:C:G	C104S	0.998
1:16975706:C:T	C104Y	0.998
1:16975707:A:G	C104R	0.998
1:16975707:A:T	C104S	0.998
1:16975712:T:C	Y102C	0.998
1:16975292:C:T	C142Y	0.997
1:16975293:A:G	C142R	0.997
1:16975301:C:G	R139P	0.997
1:16975307:C:A	C137F	0.997
1:16975700:C:G	R106P	0.997
1:16975013:A:C	C153W	0.996
1:16975014:C:T	C153Y	0.996
1:16975291:A:C	C142W	0.996
1:16975653:A:G	C122R	0.996
1:16975694:T:C	Y108C	0.996
1:16975695:A:C	Y108D	0.996
1:16975697:A:G	L107P	0.996
1:16975701:G:T	R106S	0.996
1:16975706:C:A	C104F	0.996

dbSNP variants (sampled 300 via entrez): RS1000041067 (1:16979759 C>G,T), RS1000159405 (1:16978992 T>C), RS1000317852 (1:16978799 A>C), RS1001165953 (1:16980849 C>T), RS1001446802 (1:16981203 G>A), RS1001548947 (1:16980147 T>A,G), RS1001896440 (1:16980928 T>G), RS1001982371 (1:16974305 C>T), RS1002063425 (1:16979891 C>A), RS1002248346 (1:16974974 G>A,T), RS1002482617 (1:16975601 C>G), RS1002664969 (1:16981313 G>T), RS1003517931 (1:16976203 G>A,C), RS1003642549 (1:16982147 A>C), RS1003673 (1:16978753 C>T)

Disease associations

OMIM: gene MIM:156790 | disease phenotypes:

GenCC curated gene-disease

Mondo (0):

Orphanet (0):

HPO phenotypes

0 total (0 of 0 shown, HPO-id order):

GWAS associations

65 associations (top):

Study	Trait	p-value
GCST000817_113	Height	4.000000e-29
GCST001248_3	Pulmonary function	8.000000e-16
GCST001784_26	Pulmonary function (smoking interaction)	2.000000e-11
GCST001956_54	Height	5.000000e-15
GCST002647_5	Height	1.000000e-40
GCST002702_24	Height	2.000000e-25
GCST004063_107	Waist circumference adjusted for body mass index	3.000000e-08
GCST004063_135	Waist circumference adjusted for body mass index	9.000000e-12
GCST004063_95	Waist circumference adjusted for body mass index	4.000000e-16
GCST004185_47	Lung function (FEV1/FVC)	1.000000e-10
GCST004500_28	Waist circumference adjusted for BMI (adjusted for smoking behaviour)	3.000000e-16
GCST004500_77	Waist circumference adjusted for BMI (adjusted for smoking behaviour)	1.000000e-11
GCST004500_92	Waist circumference adjusted for BMI (adjusted for smoking behaviour)	5.000000e-08
GCST004501_112	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction)	3.000000e-19
GCST004501_113	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction)	2.000000e-12
GCST004501_114	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction)	1.000000e-08
GCST004503_7	Waist circumference adjusted for BMI in smokers	1.000000e-09
GCST004504_83	Waist circumference adjusted for BMI in non-smokers	3.000000e-09
GCST004504_84	Waist circumference adjusted for BMI in non-smokers	4.000000e-12
GCST004562_117	Waist circumference adjusted for body mass index	7.000000e-14
GCST004562_160	Waist circumference adjusted for body mass index	4.000000e-10
GCST004562_253	Waist circumference adjusted for body mass index	8.000000e-13
GCST004562_6	Waist circumference adjusted for body mass index	3.000000e-11
GCST004562_65	Waist circumference adjusted for body mass index	7.000000e-10
GCST004563_142	Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction)	1.000000e-11
GCST004563_154	Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction)	6.000000e-06
GCST004563_214	Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction)	2.000000e-13
GCST004563_37	Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction)	2.000000e-10
GCST004563_53	Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction)	3.000000e-14
GCST004564_15	Waist circumference adjusted for BMI in active individuals	4.000000e-10

EFO canonical traits (13, from GWAS)

EFO ID	Trait name
EFO:0003892	pulmonary function measurement
EFO:0004713	FEV/FVC ratio
EFO:0007789	BMI-adjusted waist circumference
EFO:0004318	smoking behavior
EFO:0008002	physical activity measurement
EFO:0004341	body fat distribution
EFO:0004312	vital capacity
EFO:0009718	peak expiratory flow
EFO:0004346	neuroimaging measurement
EFO:0004840	cortical thickness
EFO:0008039	BMI-adjusted hip circumference
EFO:0004980	appendicular lean mass
EFO:0007788	BMI-adjusted waist-hip ratio

Drugs & pharmacology

Drug and pharmacology data

Is drug target: no

PharmGKB: 1 entry (VIP=true, CPIC=false)

CTD chemical–gene interactions

54 total (human), top 30 by PubMed support.

Chemical	Actions (top 5)	PubMed papers
Valproic Acid	affects expression, increases expression, increases methylation	4
bisphenol A	decreases expression, decreases methylation, increases expression	3
Estradiol	affects cotreatment, increases expression, decreases expression	3
(+)-JQ1 compound	decreases expression	2
Isotretinoin	decreases expression, increases expression	2
Particulate Matter	decreases expression, increases abundance, increases expression	2
bisphenol F	increases expression	1
4-oxoretinoic acid	decreases expression	1
titanium dioxide	affects binding, increases expression	1
beta-lapachone	decreases expression	1
arsenite	decreases expression, increases methylation	1
sulforaphane	decreases expression	1
tris(1,3-dichloro-2-propyl)phosphate	decreases expression	1
sodium arsenite	increases expression	1
benzo(e)pyrene	increases methylation	1
perfluorooctane sulfonic acid	increases expression	1
4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide	affects cotreatment, increases expression	1
bisphenol B	increases expression	1
LDN 193189	affects cotreatment, increases expression	1
NSC 689534	affects binding, increases expression	1
bisphenol AF	increases expression	1
Resveratrol	affects cotreatment, decreases expression	1
Temozolomide	decreases expression	1
Decitabine	affects expression	1
Sunitinib	increases expression	1
Alitretinoin	decreases expression	1
Acetaminophen	increases expression	1
Air Pollutants	decreases expression, increases abundance	1
Arsenic	decreases methylation	1
Vehicle Emissions	increases abundance, increases expression	1

Clinical trials (associated diseases)

0 trials via MONDO — disease-level, not drug-specific.